Compare Eli Lilly And Co (LLY) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Yum! Brands, Inc. — how do they compare? Eli Lilly And Co trades at $1,159.31 (market cap $1.02T), while Yum! Brands, Inc. trades at $147.13 (market cap $40.62B). The key difference: Eli Lilly And Co is far larger — about 25.1× Yum! Brands, Inc.'s market cap, and Yum! Brands, Inc. pays the higher dividend (2.04%). Which is the better fit depends on your goals.
| LLY | YUM | |
|---|---|---|
Market Cap | $1.02T | $40.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $168.16 |
52-Week Low | $625.65 | $138.21 |
Enterprise Value | $1.06T | $51.88B |
Dividend Yield | 0.6% | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
YUM trades at $147.44, down 0.32% amid bearish technical signals and negative news flow from a Taco Bell lettuce contamination outbreak. Fundamentally, the company shows revenue growth to $8.21B in 2025 with strong net income margins of 20.48%, though valuation ratios like P/E of 23.86 appear elevated. Recent earnings have been mixed with Q1 2026 beating expectations but Q4 2025 missing estimates.
The stock faces near-term headwinds from the food safety crisis but maintains analyst support with a $177 consensus target representing 20% upside. Long-term growth prospects remain intact with digital expansion and brand strength, though high debt levels and competitive pressures present ongoing risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
